B lymphocytes, commonly called B cells, are white blood cells responsible for producing antibodies. They are one of two main types of lymphocytes in your immune system (the other being T cells), and they form the backbone of what immunologists call “humoral immunity,” the branch of your defenses that works through antibodies circulating in your blood and body fluids. Without functional B cells, your body cannot mount a targeted antibody response to infections.
Where B Cells Come From
B cell production is a lifelong process. During fetal development, B cells first arise in the liver. After birth, the bone marrow takes over as the primary site where B cells are made and matured. This continues throughout your entire life, with the bone marrow steadily generating new B cells from blood-forming stem cells.
The journey from stem cell to mature B cell involves several stages. Stem cells progress through early forms called pro-B cells and pre-B cells before becoming fully mature. At each stage, the developing cell rearranges its genes to build a unique receptor on its surface. This receptor determines which specific foreign substance, or antigen, that particular B cell will recognize. By the time a B cell leaves the bone marrow, it carries a one-of-a-kind receptor tuned to detect one specific molecular shape. Your body produces millions of B cells with different receptors, creating an enormous library of potential matches for almost any pathogen you might encounter.
How B Cells Recognize Threats
Each B cell is equipped with a surface receptor called a B cell receptor, or BCR. This receptor is essentially an antibody molecule anchored to the cell’s outer membrane, and it has the same antigen specificity as the antibodies the B cell will eventually secrete if activated. When the BCR encounters its matching antigen, it latches on. The receptor itself can bind the antigen but cannot generate a signal on its own. It relies on partner proteins embedded alongside it in the cell membrane to relay the “match found” message into the cell’s interior.
This is a key distinction from T cells: B cells can recognize antigens in their natural, unprocessed form floating freely in blood or tissue fluid. T cells, by contrast, only recognize fragments of antigens that have been processed and displayed on the surface of other cells.
Activation and the Role of Helper T Cells
Finding a matching antigen is only the first step. For most threats, B cells need a second confirmation signal before they fully activate. This signal comes from helper T cells in a process called T cell-dependent activation.
Here’s how it works. After a B cell binds its target antigen, it swallows and digests the antigen, then displays fragments of it on its surface using special molecules called MHC class II. This makes B cells “professional antigen-presenting cells,” a designation they share with immune cells like dendritic cells and macrophages. A helper T cell that recognizes the same antigen fragment then docks with the B cell. The T cell provides co-stimulation through direct cell-to-cell contact and releases signaling molecules (particularly ones called IL-4 and IL-21) that push the B cell to multiply and mature. This two-step verification system prevents B cells from firing off antibodies against harmless substances or your own tissues.
Some antigens, particularly repetitive molecular structures found on bacterial surfaces, can activate B cells without T cell help. These T cell-independent responses are faster but generally produce a less refined antibody response.
Plasma Cells: The Antibody Factories
Once activated, B cells can differentiate into plasma cells, which are essentially antibody-manufacturing machines. A single human plasma cell can produce between 100 and 10,000 antibody molecules per second. These antibodies flood into the bloodstream and tissues, where they neutralize pathogens, mark them for destruction by other immune cells, or trigger inflammatory responses that help clear the infection.
Plasma cells are so specialized for antibody production that they lose some of their other capabilities. They no longer display MHC class II molecules on their surface, meaning they can no longer present antigens to T cells or undergo further changes to the type of antibody they produce. They are, in effect, locked into one job.
Antibody Types and Class Switching
B cells don’t just produce one kind of antibody. They start by making a general-purpose type called IgM, but with the right signals, they can switch to producing other classes tailored to specific situations. This process, called class switching, is directed by signaling molecules from helper T cells and other immune cells.
- IgG: The most abundant antibody in blood, effective against bacteria and viruses. Different subtypes are promoted by different immune signals.
- IgA: The dominant antibody in mucous membranes, saliva, and breast milk. A growth factor called TGF-beta drives the switch to IgA production.
- IgE: Involved in allergic reactions and defense against parasites. IL-4, a signaling molecule from helper T cells, is required for IgE production.
The antibody class a B cell produces determines where and how it fights. IgA protects your gut and respiratory lining. IgG circulates in the blood and crosses the placenta to protect newborns. IgE triggers the histamine release responsible for allergy symptoms. The same B cell lineage can be redirected to produce whichever class is most useful for the current threat.
Memory B Cells and Long-Term Immunity
Not all activated B cells become plasma cells. Some become memory B cells, which persist in the body long after an infection has been cleared. These memory cells are the foundation of lasting immunity and the reason vaccines work.
When you encounter the same pathogen a second time, memory B cells recognize it almost immediately. They can rapidly differentiate into new plasma cells, producing large quantities of high-quality antibodies far faster than the original response. Some memory B cells can also re-enter specialized structures in lymph nodes called germinal centers, where they further refine their antibody response. This is why your second encounter with a pathogen (or a booster vaccine) typically produces a stronger, faster immune response than the first.
Long-term immune protection is a partnership: long-lived plasma cells maintain a steady baseline level of circulating antibodies, while memory B cells serve as a reserve force that can be rapidly mobilized if antibody levels aren’t enough to contain a new exposure.
B Cell Numbers in Healthy Adults
B cells make up roughly 5% to 15% of the lymphocytes circulating in your blood. The majority of your B cells actually reside in lymph nodes, the spleen, and other lymphoid tissues rather than in the bloodstream itself. Within the circulating B cell population, there is considerable variety: different subsets carry different surface markers and play distinct roles. About 75% of normal circulating B cells carry a surface marker called IgD, which is characteristic of mature but not yet activated cells.
What Happens When B Cells Don’t Work
B cell deficiencies are actually the most common category of primary immune deficiency disorders. They range from mild to severe, depending on which part of B cell development or function is impaired.
The classic example is X-linked agammaglobulinemia (XLA), first described in 1952 in a boy with recurrent bacterial infections and virtually no antibodies in his blood. In XLA, a genetic mutation blocks B cell development in the bone marrow, so patients have almost no circulating B cells and cannot produce antibodies on their own. They require regular infusions of donated antibodies to stay healthy.
Common variable immunodeficiency (CVID) is more prevalent, affecting roughly 1 in 25,000 to 1 in 50,000 people. Unlike XLA, people with CVID typically have B cells, but those cells fail to produce adequate amounts of antibodies. Most patients are diagnosed between ages 20 and 45 and experience recurrent sinus and lung infections. Selective IgA deficiency is even more common, with rates varying widely by ethnic background, from about 1 in 143 to 1 in 18,500 people worldwide. Many people with IgA deficiency have no symptoms at all, while others are more prone to respiratory and gastrointestinal infections.
B Cells in Cancer and Autoimmune Disease
Because B cells can multiply rapidly, they are susceptible to becoming cancerous. Lymphomas and certain types of leukemia arise from B cells at various stages of development. One of the most significant advances in treating these cancers has been the development of therapies that target a protein called CD20, which is found on the surface of most B cells. The drug rituximab, an antibody designed to bind CD20 and destroy B cells carrying it, has been shown to improve survival when added to standard chemotherapy for B cell lymphomas.
The same approach has proven useful in autoimmune diseases, where B cells mistakenly produce antibodies against the body’s own tissues. By temporarily depleting B cells with anti-CD20 therapy, doctors can reduce the autoimmune attack. This strategy is now used in conditions like rheumatoid arthritis and certain forms of multiple sclerosis, illustrating just how central B cells are to both protective immunity and immune-mediated disease.